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Adult-onset osteoporosis is a disorder that affects a significant proportion of the elderly 
population worldwide and entails a substantial disease burden for the affected individuals. 
Childhood-onset osteoporosis is a rare condition often associating with a severe bone disease 
and recurrent fractures already in early childhood. Both childhood-onset and adult-onset 
osteoporosis have a large genetic component, but in children the disorder is usually 
genetically less complex and often caused by a single gene variant. This makes genetic 
studies a well-suited approach to explore primary osteoporosis in children, which is the focus 
of this thesis. Genetic studies can also be used to study bone metabolism in healthy children 
because of the dynamic stage of the skeleton during growth. Studies in children also have the 
advantage of involving less confounding environmental factors and other co-morbidities than 
studies in adults. 
 
Our genetic studies had two main goals. First of all, for individuals affected with a severe 
bone phenotype, a molecular diagnosis is important for several reasons, but particularly for 
prognostic purposes and for decisions related to treatment strategy. Secondly, the hope is that 
uncovering genetic regulators of bone metabolism in severely affected children will reveal 
universal mechanisms that are important also for the adult osteoporosis population. Paper I 
and Paper II had a monogenic focus and investigated individuals with childhood-onset 
osteoporosis or fracture propensity. In Paper I we identified two novel disease-causing 
variants in the PLS3 (Plastin 3) gene. The findings allowed us to conclude that PLS3 
screening should be recommended in children with primary osteoporosis, especially if 
vertebral compression fractures are a dominant feature. In Paper II we showed for the first 
time that PLS3 gene deletions can cause osteoporosis in children. We also found evidence 
suggesting that PLS3 has an important role in bone matrix mineralization. Paper III and 
Paper IV approached bone health as a polygenic trait. In Paper III we explored, for the first 
time, the polygenic contribution to osteoporosis in children with presumed monogenic bone 
phenotypes. The study findings suggest that a proportion of the children with severe bone 
phenotypes and a suspected monogenic etiology for osteoporosis instead may have a 
polygenic cause underlying the disorder. Finally, in Paper IV we show that the genes GC 
and CYP2R1 are important determinants of the 25(OH)D concentration in 24-month-old 
healthy children. Using a Mendelian randomization approach, we also provide support for a 
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1.1.1. What is osteoporosis? 
Osteoporosis is defined as a “systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility 
and susceptibility to fracture” [1]. This explanatory, or soft, definition of osteoporosis reflects 
the true nature of osteoporosis as a metabolic bone disease. The unhealthy bone is weaker 
than healthy bone and this increases the risk of fractures. Bone fragility in turn is a severe 
condition that has significant implications both on the individual level and for the society. 
Osteoporotic fractures, or fragility fractures, of the hip and vertebrae are associated with a 
high and immediate mortality risk, especially in the elderly population, and lead to great costs 
for the healthcare system [2]. Fragility fractures of the hip and vertebrae are the most 
hazardous fractures, but studies have shown increased mortality also for non-vertebral, non-
hip fractures. The increase in mortality is the highest during the first year after the fracture, 
but remains elevated for up to 10 years [2-4]. Osteoporosis and the fragility fractures caused 
by the disease are thus a major threat to the affected individuals and to public health and a 
major economic issue for our healthcare system. It is therefore of great importance to better 
understand the pathogenesis and underlying biology of osteoporosis. This will hopefully 
enable more precise predictions for an individual’s fracture risk and development of new 
treatment strategies. Improved osteoporosis care will become even more relevant in the 
future, as fragility fractures are predicted to steadily increase due to population aging [5].   
 
1.1.2 Diagnosis of osteoporosis 
Research initiatives to understand the underlying mechanisms and biology of osteoporosis 
face many difficulties. One fundamental difficulty is the definition of the disease – how to 
decide which patients should be given the diagnosis of osteoporosis. The most encompassing 
and true definition of osteoporosis would be a definition that could precisely describe the 
metabolic disturbance in the bone tissue that eventually leads to the clinically most significant 
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event, the fracture. However, like many other diseases, the clinical definition of a condition 
needs to be standardized, non-arbitrary and not too difficult to measure. Because of that, a 
proxy measurement is often used to make the diagnosis, and for osteoporosis that proxy 
measurement is bone mineral density (BMD). For the last 30 years osteoporosis has been 
defined as a dual-energy x-ray absorptiometry (DXA) derived BMD (measured at the hip) of 
equal or more than -2.5 standard deviations below the average BMD in young white women 
[6]. In practice however, the -2.5 SD cutoff is more widely used, and is not always confined 
to hip DXA measurements or the original reference population. This diagnostic criterion of a 
DXA-derived BMD ≤ -2.5 SD for osteoporosis was established by the WHO study group in 
1992 because it was viewed as the best indicator for the disease [7]. However, it is likely that 
the cutoff of a BMD ≤ -2.5 SD was chosen semi-arbitrarily.  
Although widely used, this definition has also been criticized for its lack of specificity when 
it comes to discriminating patients with true osteoporosis and increased risk of fractures from 
individuals without osteoporosis or increased fracture risk [8]. Further, BMD displays a 
normal distribution in the population, and no “hump” in the curve can be observed for 
individuals in the lower BMD ranges, suggesting that BMD does not capture or separate any 
specific subgroup of individuals with a specific condition [8]. Although BMD is arguably still 
the best single measurement for estimation of bone strength and prediction of fracture risk, an 
individual’s age supersedes BMD by far as a fracture risk predictor [9, 10]. Taken together 
BMD should be considered a relevant, but somewhat blunt, measurement to identify 
individuals with a metabolic bone disease and an increased fracture risk. Individuals with a 
diagnosis of osteoporosis thus represent a very heterogenous group with various underlying 
causes for low BMD. Furthermore, although the risk of fractures is higher in individuals with 
very low BMD, the majority of fractures occur in the group which the WHO definition 
describes as having ‘osteopenia’, or a BMD above -2.5 SD, but below -1.0 SD [11, 12].  
 
1.1.3 Multifactorial etiology of low BMD 
Normally peak bone mass is reached early in adulthood when growth ceases. An individual’s 
bone mass then slowly starts to decline with age, and in women this decline is especially fast 
after menopause [13]. A low bone mass, resulting in a diagnosis of osteopenia or 
osteoporosis, can thus be due to either an accelerated bone loss later in life or a decelerated 
bone growth earlier in life. Both scenarios can lead to a diagnosis of osteoporosis, but the 
underlying mechanisms for the disease will likely be different.  
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Various factors affect bone mass accrual and skeletal health during childhood. Especially for 
children living in the northern latitudes, such as in Sweden or Finland, vitamin D is an 
important factor. Severe vitamin D deficiency can lead to poorly mineralized bone, a disorder 
called rickets in children and osteomalacia in adults [14, 15]. A Finnish study showed that 
vitamin D concentration is a major determinant for BMD in adolescents [16]. Several other 
factors can also affect bone mass accrual or maintenance, including a variety of underlying 
medical conditions, medications, ethnicity, physical activity and other life-style factors (for 
example smoking and diet) [6]. Since there are so many different reasons for low bone mass, 
there are most probably also several different biological and cellular mechanisms leading to a 
low BMD. This lack of homogeneity in patients with a DXA-derived diagnosis of 
osteoporosis constitutes a major challenge for the research field. Because scientific 
conclusions often are based on group comparisons, it is imperative that the biological (not 
only measured) phenotype of the individuals in each group used for comparisons is correct, 
meaningful and also somewhat similar. Unfortunately, BMD only captures part of the 
osteoporosis phenotype and does not separate the mechanisms leading to low bone mass. 
 
1.1.4 Pediatric osteoporosis 
Early-onset/childhood-onset osteoporosis is a special entity within osteoporosis. The term 
childhood-onset osteoporosis describes fragile bone with a propensity to fracture in 
childhood. The most recent (2019) Official Position by The International Society for Clinical 
Densitometry (ISCD) defines pediatric osteoporosis as: A) a BMD Z-score < -2.0 AND B) a 
clinically significant fracture history defined as 1) two or more long bone fractures by age 10 
years OR 2) three or more long bone fractures at any age up to age 19 years. The fracture 
criterion (B) is important because BMD in children is largely affected by the child’s bone size 
/ height and pubertal development [17]. Because children grow and develop in different rates 
it can be difficult to compare children’s BMD, even if they are the same age. Therefore, the 
diagnosis of osteoporosis also requires that the child has an abnormal fracture history. An 
exception is vertebral compression fractures, which are considered more powerful in 
predicting osteoporosis in children [18]. The diagnosis of osteoporosis in children can 
therefore be made if vertebral fractures are present even if BMD is normal. The requirement 
of a clinically significant fracture history is a necessity in children for biological reasons, but 
it also adds a functional component to the diagnosis. This functional criterion, which is 
lacking for adults, might lead to better identification of children with ‘true’ osteoporosis. 
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1.2 Genetics of osteoporosis 
 
1.2.1 Genetics underlying osteoporosis in children 
The distinction between primary and secondary osteoporosis is important, especially when 
the diagnosis of osteoporosis is considered in a child. Primary osteoporosis in children is a 
term used to emphasize that the bone condition is primary, or inherent, and cannot be 
explained by any other underlying disease, medication or other external factors. In contrast, in 
secondary osteoporosis exogeneous factors lead to osteoporosis [18, 19]. Primary 
osteoporosis in children is a rare and often severe disease. It often has a more direct genetic 
component with familial clustering, and in many cases a single gene variant can explain the 
full phenotype seen in the child [20]. The Mendelian, or monogenic, nature of primary 
osteoporosis in children opens up the possibility to conduct family studies, in which 
heterogeneity of a disorder is no longer a problem. Family studies also have a great advantage 
in the aspect that they are not bound by the strict definitions of a disease. Phenotyping of a 
family can be much more specific and detailed than what the standard definition of 
childhood-onset osteoporosis (or adult-onset osteoporosis) can capture. In family studies, 
experienced clinicians thus have the possibility to identify and delineate rare bone conditions 
in a specific and detailed manner. Uncovering the underlying genetics in these rare families 
can reveal novel genetic mechanisms directly involved in bone metabolism. Since some 
families have a very rare or perhaps even private bone condition, genetic causes underlying 
such disorders cannot be identified in cohort studies, where the methodology is based on 
comparisons between groups. In such group comparisons, these rare causes and disease 
mechanisms become too diluted and will escape detection. Using a family-based approach for 
genetic studies therefore has the possibility to uncover mechanisms that cannot be detected 
when studying larger patient cohorts of unrelated individuals.  
 
1.2.2 Monogenic osteoporosis in children 
The largest subgroup of children with primary osteoporosis will get the diagnosis 
Osteogenesis imperfecta (OI) [19, 21] OI is originally a clinical diagnosis and defined as a 
connective tissue disorder that is primarily characterized by susceptibility to fractures 
throughout life [22, 23]. This wide definition of OI will include a fairly large and very 
heterogenous group of patients and distinction from other forms of primary osteoporosis is 
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often challenging. However, in practice, the diagnosis of OI is most often confined to 
individuals with a clinically more severe bone fragility phenotype associated with typical 
extra-skeletal features such as blue sclerae and where a monogenic cause almost always can 
be confirmed [24, 25]. Yet, even if using a narrow definition of OI and only considering 
patients with a known monogenic cause, the group as a whole is still very heterogenous. The 
osteogenesis imperfecta database [26], contained within the Leiden open variation database, 
today reports pathogenic variants in 20 genes as the underlying cause of OI. However, not all 
genetic forms of primary osteoporosis are included [22, 27, 28].  
 
1.2.3 Classification of Osteogenesis imperfecta 
The classification of Osteogenesis imperfecta has traditionally been based on the Sillence 
classification from 1979. In the Sillence classification patients with OI were divided into 4 
subgroups (OI I-IV), with the addition of a fifth subgroup in 2000 (OI V with very specific 
radiologically findings) [23, 29]. The Sillence classification is a clinical classification that 
relies on the phenotypic presentation and severity, radiological findings and inheritance 
pattern of the disorder [22]. The traditional classification is preferred because with discovery 
of more and more genes underlying OI, it has become a practice to add a new subtype of OI 
to the classification for each new gene discovery. This newer type of classification, which 
first seemed logical, has evolved on its own and has become confusing. Today OMIM reports 
20 different OI types (OI I-XX), but this long list of different subtypes has only little clinical 
relevance. When the traditional OI classification was developed in 1979 the underlying 
genetic causes of OI were not known, but it had already been shown that defects in collagen 
production and collagen crosslinking were involved in the disorder [30, 31]. Today we know 
that OI is predominantly a type I collagen related disorder [24]. Pathogenic variants 
(including both single nucleotide variants (SNVs) and structural variations (SVs)) in the 
genes COL1A1 and COL1A2 explain the great majority (about 90%) of OI cases [32]. It has 
also been suggested that the diagnosis of OI should be used only for bone disorders caused by 
type I collagen defects, but presently no clear consensus exists [22, 33].  
 
1.2.4 Osteogenesis imperfecta and type I collagen 
 COL1A1 and COL1A2 are the genes that produce the pro-α1 and pro-α2 chains that after post 
translational modifications, cleavage and added stabilizing crosslinks will come to form 
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mature collagen type I, the most abundant protein in bone [34]. Mature collagen type I 
consists of two α1-chains and one α2-chain that assemble into a triple helix, many triple 
helices are then crosslinked together to form fibrils, which in turn can bundle into thicker 
fibers [35]. The collagen fibrils in bone are often compared to iron bars used to reinforce 
concrete, but they also make up the scaffold in the extra cellular matrix (ECM) that helps the 
bone to mineralize. Collagen fibrils in the ECM take active part in the mineralization process, 
both in the nucleation and in the orientation of hydroxyapatite crystals that eventually will 
make up the largest proportion of any component in bone [36]. Because collagen has such an 
important role in bone, providing strength and elasticity to the mature bone and actively 
taking part in its formation, it is understandable that genetic aberrations affecting the two 
genes encoding type I collagen can cause bone disorders. However, since mature collagen is 
the result of a very complex post-translational processing, also pathogenetic variants in genes 
involved in the maturation steps of type I collagen can give rise to type I collagen related OI. 
The majority of the 20 genes underlying OI are known to affect collagen, either in a direct or 
indirect fashion. Yet, there are OI cases that are due to pathogenic variants in genes not 
related to collagen production or processing, and instead other pathways are affected. This 
has led to the suggestion that the OI classification should rely on the underlying metabolic 
pathway that is compromised in each specific case. In a fairly recent review article, Forlino et 
al. suggested to divide OI forms into five functional groups (A-E) [Table 1] to emphasize the 
biological aspect of each different sub-type [24]. This type of newer classification system, 
which utilizes recent advances in understanding the molecular cause of a genetic disorder and 
places each form into a biological context depending on which pathway is affected, is much 
more informative than classifications that solely rely on clinical or genetic features. Such a 
classification will probably allow clinicians to give more accurate estimates of prognosis and 
enable identification of patient groups that might respond similarly to treatment strategies. 
This type of classification would also circumvent some of the inconsistencies seen in current 
classifications, where pathogenic mutations in WNT1 are classified as OI, while pathogenic 
variants in LRP5 causing primary osteoporosis are not [28, 37]. WNT1 and LRP5 does, 





Table 1. Proposed functional classification of Osteogenesis imperfecta 
   
Gene symbol Severity Inheritance 
Defects in collagen synthesis, structure, 
or processing (group A) 
  
COL1A1 mild to severe AD 
COL1A2 mild to severe AD 
BMP1 mild to severe AR 
   
Defects in collagen modification (group B)  
CRTAP severe rhizomelia AR 
LEPRE1/P3H1 severe rhizomelia AR 
PPIB severe AR 
TMEM38B severe AR    
Defects in collagen folding and cross-linking (group C) 
 
SERPINH1 severe AR 
FKBP10 mild to severe AR 
PLOD2 moderate to severe AR 
   
Defects in bone mineralization (group D) 
  
IFITM5 mild to severe AD 
SERPINF1 moderate to severe AR 
PLS3* mild to moderate 
 
XL 
Defects in osteoblast development with 
collagen insufficiency (group E) 
 
 
SP7 severe AR 
WNT1 moderate-severe AD/AR 
CREB3L1 severe AR 
*PLS3 was not included in the original classification, but has in this thesis been placed in group D. [Autosomal 




1.3 Approaches to decipher underlying mechanisms in osteoporosis 
 
1.3.1 Different angles to approach bone biology in research 
The higher purpose for all medical research focusing on human disorders is to enhance 
understanding of the underlying biology. Increasing knowledge of a disorder facilitates 
improvement of clinical management and treatment strategies, and thus helps the affected 
patient. Also, the hope is often (or always) to provide tools and ideas for the development of 
new pharmaceutical drugs to further improve the affected patients’ health, or in a best-case 
scenario, to cure the disorder. What constitutes a disease or disorder can however be debated 
– especially when it comes to a disorder like osteoporosis. It can be questioned whether a low 
BMD in a 90-year-old individual can be considered a disorder or just normal aging. In many 
ways, these questions may not be important. Instead the important question is whether a 
treatment (or similar) would benefit a person with a specific condition, regardless of whether 
that condition is normal or not. This means that the full breadth of the disease – from 
defective bone accrual in children to age-related bone loss in the elderly – needs to be 
investigated further. The quest to uncover the underlying bone biology can be approached 
from different angles, where each angle will have its own pros and cons. 
 
1.3.2 The genetic approach 
One way to tackle the important questions in bone biology is to use genetics as the angle of 
attack. To improve clarity and to minimize the effect of confounding environmental factors 
and co-morbidities frequently present in adult or elderly cases, it can be advantageous to 
study osteoporosis in children. In children, the bone tissue is also in a much more critical and 
dynamic stage than in adults, because during growth a large quantity of bone needs to be 
accumulated in a short period of time. In such a situation, a defect in bone metabolism might 
be more visible, and findings might have more direct relevance for the actual trait (bone) 
under scrutiny. To study a disorder like osteoporosis in an elderly population is more 
complicated because it may be difficult to understand which factors possibly can confound 
the results. Also factors that seem to have a true causal effect on adult osteoporosis can just as 
well be the result of reversed causality. The interpretation of study results can therefore be 
difficult, even if methods do exist to address these issues [40].  
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1.3.3 Rare phenotype approach 
As discussed above, disorders with a childhood onset are often less multifactorial than 
disorders with an adult onset. From a genetic perspective this means that undertaking genetic 
studies on individuals/families with a rare and severe phenotype that presents already in 
childhood will have a greater chance for success than studying less clear phenotypes where 
environmental factors are likely to explain a larger proportion of the cases. This is best done 
using carefully selected families where the inheritance pattern suggests, or confirms, that the 
disorder is inherited. The rarity of the phenotype (in this thesis primary osteoporosis in 
children) is not important in itself and is most often just a consequence of the severity of the 
disorder. The fact that the disorder is severe does, however, imply that a central mechanism is 
affected and can, if identified, confidently be assumed to be of direct importance. This type of 
approach has been proven successful in a variety of human disorders [41], but also in the field 
of bone metabolism. In 2001 several different research groups identified the cause of (1) 
Osteoporosis-pseudoglioma syndrome (OPPG), a low bone mass syndrome with extra-
skeletal features and (2) Sclerosteosis, a high bone mass disorder [42-44]. Biallelic 
pathogenetic variants in the gene LDL Receptor Related Protein 5 (LRP5) were found to 
cause OPPG, and one year later in 2002, a pathogenic variant in a specific domain of the 
LRP5 gene was shown to cause an autosomal dominant high bone mass disorder [45]. For 
Sclerosteosis biallelic null-variants in the gene sclerostin (SOST) were discovered to be the 
cause of the high bone mass syndrome and in 2002 a homozygous large deletion affecting the 
regulation of SOST was shown to cause the phenotypically similar disorder Van Buchem 
disease [46]. These genetic discoveries, made possible by genetic studies in families with rare 
phenotypic presentations, led to the understanding that WNT signaling is one of the most 
important pathways for bone tissue homeostasis [39]. A promising new osteoporosis drug, an 
anti-sclerostin antibody, that blocks the WNT-signaling inhibitor sclerostin was also 
developed as a result of the studies in these families [47]. After its discovery, anti-sclerostin 
antibody treatment was anticipated to become a powerful tool in osteoporosis care. Treatment 
trials have shown convincing results [47], but suspected adverse cardiovascular events have 
limited the popularity first foreseen [48]. However, despite this drawback, the story of how 
WNT signaling was found to be one of the most import signaling pathways in bone elegantly 
shows the full strength of a family-based rare phenotype approach. The benefits are twofold, 
because the results were important both for the individuals affected by these rare disorders 
and for the general population. The individuals studied received a molecular diagnosis and 
much knowledge about their condition was gained. The results were also generally 
applicable, because the genetic findings revealed a universally important pathway for bone 
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homeostasis, and manipulation of this pathway could in the future help patients with a variety 
of low bone mass disorders. The story thus displays that one of the basic ideas of the rare 
phenotype approach can work – that severely affected individuals with suspected 
(mono)genic disorders will have aberrations in fundamental mechanisms or pathways for the 
affected tissue(s). New pharmaceutical drugs developed to manipulate these fundamental 
mechanisms or pathways can in turn provide a treatment option also for other more common, 
but similar, disorders.  
 
1.3.4 Approaching the polygenicity of osteoporosis 
Adult-onset osteoporosis is a complex trait with a large heritable component [49, 50]. This 
statement is most certainly true for a subgroup of children with primary osteoporosis as well, 
but because of the rarity of the disorder, the polygenetic contribution is more difficult to 
study. To decipher the underlying polygenetic component of osteoporosis, one approach (as 
already discussed) is to study rare phenotypes and build the puzzle one piece at a time. 
However, not all results from studies of monogenic osteoporosis can be extrapolated to the 
more common form of complex osteoporosis [51]. Instead, another approach is to directly 
study the polygenic structure of a trait using a genome-wide association study (GWAS) 
approach. The basic principle of a GWAS relies on the idea of comparing genotype 
frequencies between or within groups. To understand the concept of a GWAS, the case-
control study using a dichotomous trait (osteoporosis vs not having osteoporosis) is 
intuitively easiest to understand, but a GWAS often performs better if the studied trait is 
quantitative [52]. In a basic case-control GWAS common biallelic single nucleotide 
variants/polymorphisms (often referred to as SNVs/SNPs) are genotyped at certain intervals 
throughout the genome while taking linkage disequilibrium (LD) structure into account. The 
genotypes for each location in the genome are then compared between individuals with the 
trait (osteoporosis) and individuals without the trait (not having osteoporosis). If the 
genotypic distribution at a certain genomic position differs between the cases and controls, 
and the observed difference cannot statistically be explained by coincidence, then the SNP at 
that certain genomic position can be regarded as being associated with the trait (osteoporosis). 
The results cannot tell if the associated SNP has an effect in itself on the studied trait, but it 
can tell that the cause for the association should exist somewhere in the genomic vicinity of 
that SNP (i.e. the genomic region in LD with that SNP). A GWAS can therefore pinpoint 
genomic regions of importance for a trait, even though it cannot identify the actual genetic 
cause behind the association signal. The hope is that the underlying genetic cause behind the 
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association signal is directly linked with the trait’s biology, here osteoporosis, meaning 
something that would have a direct biological impact on bone metabolism. However, the 
genetic cause for an association signal in a GWAS does not necessarily have a direct impact 
on the trait being studied. If we consider a situation where a genetic variant increases an 
individual’s risk to become addicted to smoking, and smoking in turn affects another trait (for 
example cardiovascular disease), then the same variant could give rise to an association 
signal in a cardiovascular GWAS. In this example the variant does increase an individual’s 
risk for cardiovascular disease, but only if that individual actually starts to smoke, otherwise 
it does not. Although GWASes lack the ability to identify underlying causative genetic 
aberrations, GWASes have been a success story from the beginning, also for the trait 
osteoporosis [51, 53, 54].  
 
1.3.5 GWAS - Strength and weakness 
The major caveat with a GWAS design is that of power. GWASes suffer from power 
problems mainly because of two reasons: 1) The target traits in GWASes are polygenic in 
nature, but the study design essentially only allows separate assessment of each variant. 
Because of that, the study needs to be powered to find variants with a very small effect size. 
2) In a GWAS millions of variants are separately assessed, or at least semi-separately 
assessed (depending on LD structure), meaning that adjustment for multiple testing will have 
a major impact. However, large international collaborations and consortiums have been 
developed through the years to overcome these power problems and GWASes nowadays can 
include even up to a million individuals [55-58]. In 2012 Estrada et al. performed a large 
meta-analysis on 17 GWASes including more than 30,000 individuals, which at that time was 
the largest DXA-derived GWAS performed. The study was able to identify 56 BMD-
associated loci, explaining around 5% of the total variance in BMD [49]. In 2017, utilizing 
the UK biobank [56], a GWAS on estimated BMD (eBMD) derived from quantitative 
ultrasound of the heel including 142,000 individuals was able to identify 203 genetic loci 
associated with eBMD; these together explained 12% of the variance seen in the trait. More 
recently an even larger GWAS on eBMD that included >400,000 individuals identified 518 
genetic loci that together explained 20% of the variance [57]. This illustrates a fantastic 
progress in the field of bone genetics and the studies have provided vast new insight into 
bone biology. However, all GWAS findings need to be interpreted in relation to the trait 
being studied. Estimated BMD derived from quantitative ultrasound of the heel is a cost-
effective alternative for DXA-derived BMD that enables the collection of very large cohorts, 
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which is important in association studies. eBMD is independently associated with fractures, 
suggesting that it is a meaningful bone parameter to measure [59]. On the other hand, it is 
known that eBMD is not a very precise predictor of DXA-derived BMD, which in turn is 
quite a blunt measurement for ‘true’ osteoporosis [8, 60]. It can therefore be wise to interpret 
GWAS-derived genetic findings from eBMD keeping that in mind, because it is not certain 
that they fully reflect the biology underlying the disease osteoporosis.  
 
1.3.6 Monogenic vs polygenic approaches 
Comparing the rare phenotype approach (monogenic approach) to the GWAS approach 
(polygenic approach) in a simplified manner, the rare phenotype approach can identify rare 
variants with large effect sizes while GWASes are able to identify common variants with 
small effect sizes. Although recent GWASes, by leveraging WGS-data, are closing the gap 
and have now been able to identify a rarer variants with larger effect sizes [61, 62]. However, 
there is reason to believe that the rare phenotype approach more precisely targets what was 
intended. Pharmaceutical companies have for a long time tried to improve means to predict 
which new drugs will survive the clinical testing stage and eventually come out on the 
market. For pharmaceutical companies this is a pressing issue because of the high costs of 
drug development. A systematic review recently showed that if there are (human) genetic 
evidence that a new drug targets a biologically meaningful mechanism, the chances for that 
drug to come out on the market are better. The study showed that if the evidence is based on 
findings from GWASes, the evidence is good, but if it is based on findings from studies on 





1.4 Heritability of osteoporosis and fractures 
 
1.4.1 Heritable traits are suited for genetic studies 
The heritability of a trait tells about how large the inherited (i.e genetic) component of a trait 
is. Traits like the disease Phenylketonuria (PKU), which is monogenic in nature, have an 
extremely large heritability that approaches 100%. In contrast, an individual’s tea or coffee 
consumption has a low heritability and probably is the result of environmental influence [64]. 
This also means that if one was to study the biology of a trait using genetics as an angle of 
attack, the approach would be more successful in PKU than in tea drinking preference. The 
heritability of a trait will also give a hint of how much more unknown genetic information 
there is to discover beyond to what is already known.  
 
1.4.2 Heritability of osteoporosis 
Because the definition of osteoporosis in adults relies on BMD, and because BMD can be 
relatively easily and precisely measured, it is widely used in research. Genetic studies on the 
disease osteoporosis can therefore better be described as genetic studies on BMD. To 
estimate the heritability of a trait (here BMD), twin studies are often used. Comparing 
monozygotic twins with dizygotic twins for a specific trait or disease is an approach that aims 
to omit environmental factors from the equation and indirectly estimate the genetic 
component of the studied trait. Twin studies can estimate heritability without needing to 
identify the specific genetics underlying the trait. Twin studies focusing on bone have shown 
that bone parameters are highly heritable, especially BMD, where estimates as high as 85% 
have been proposed [50]. Twin studies are a good and relatively simple approach to 
circumvent unknown confounding factors that might obscure heritability estimates, although 
suspicions are strong that twin-studies overestimate the heritability [65]. Family based studies 
on extended pedigrees using data from the Genetic Analysis of Osteoporosis Project have 






1.4.3 LD score regression, and unbiased approach to estimate heritability 
Another approach to estimate the heritability of a trait is called LD score regression. LD score 
regression can estimate the SNP-heritably, which is the sum of the genetic effect that can be 
attributed to single nucleotide variants/polymorphisms. When performing an association 
analysis, it is unlikely that the causal genetic variant underlying the association signal actually 
is included in the dataset (either directly genotyped by the applied array or imputed). Instead 
the associations between the genetic markers and the trait arise because some genotyped 
SNPs will be in close proximity (genomic distance) to the causal genetic variant (that actually 
causes the association signal). Variants in close genomic proximity will most likely be 
inherited together, because they are unlikely to be separated by meiotic recombination and 
can thus be used as proxies for each other. SNPs that are inherited together are said to be in 
LD, and can be said to belong to the same haplotype. Haplotype estimation is also the basis 
for imputation, where the genotype of a SNP can be inferred even though it has not been 
directly genotyped by the array used [67]. LD score regression is based on the fact that the 
average association strength of a genetic variant (most often a SNP) to a trait will be 
dependent on the size of the genomic region that the genetic variant tags (i.e is in LD with). 
Because SNPs that tag a larger genomic region will have a greater chance to also tag a 
causative variant underlying an association signal, those SNPs will on average also have a 
stronger association to the trait. The greater the average difference in association strength 
between SNPs that tag a large genetic region and SNPs that tag a small genetic region, the 
greater is the heritability of the trait. Looking at LD regression score estimates, the 
heritability of BMD is around 30% for lumbar and femoral neck BMD, as well as for 
ultrasound estimated heel BMD [68, 69]. LD score regression has the advantage that it is not 
affected by population stratification, but does underestimate the true heritability because it 
only accounts for the heritability explained by the sum of commonly occurring SNPs, not all 
genetic factors [70]. However, even if it is not possible to precisely estimate the true 
influence genetics has on bone metabolism, it can be confidently said that BMD, and 
therefore by definition osteoporosis, is a highly heritable trait. This is an important 
conclusion, because this means that performing genetic studies on bone disorders or bone 
parameters is a good and meaningful approach to decipher bone metabolism and discover 
underlying molecular mechanism important for bone homeostasis. The SNP heritability from 





1.4.4 The etiology of fractures is more complex 
What about the genetics underlying fractures? It is important to understand if genetic studies 
on BMD or osteoporosis can lead to new insights to the clinically most important feature of 
osteoporosis, the osteoporotic fracture. Some even argue that osteoporosis should not be seen 
as a disease at all, instead it should merely be regarded as a risk factor for the real disease – 
the fracture [71]. However, only a very narrow view of what constitutes osteoporosis can 
make such an argument viable. Nonetheless, the fracture is what causes the greatest cost for 
the society, and the greatest morbidity and mortality for the affected individuals [6, 72]. A 
large Swedish twin study investigated the fracture heritability in almost 25000 twins, of 
which 6021 had sustained a fracture. The study concluded that fractures have a substantial 
genetic component, and this component explains on average around 20% of the variance in 
fracture rates. However, the heritability was strongly influenced by fracture site and age at 
fracture. The highest heritability estimate was for hip-fractures before the age of 69, where 
around 2/3 of all fractures could be explained by genetic liability. However, in individuals 
≥80 years of age the genetic composition did not seem to have a strong effect [73]. In a twin 
study conducted in Finland the authors concluded that they found little evidence for genetic 
influence on the risk of osteoporotic fractures, however, the study did only include a total of 
786 fractures [74]. SNP heritability calculated from LD score regression also suggests that 
fractures have a less strong genetic component than bone parameters [Fig. 1]. 
 
Fig. 1. SNP heritability estimated from LD score regression. The average SNP heritability of bone 
parameters, such as BMD, is fairly high while the SNP heritability of fractures is lower and more dependent on 
the specific fracture trait. (Data from  http://ldsc.broadinstitute.org/ and https://nealelab.github.io/UKBB_ldsc/.) 
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A more recent study looking at >3000 individuals from the Framingham Heart Study was 
able to estimate the heritability of vertebral compression fractures to somewhere in the range 
of 43-69%, suggesting that the risk for vertebral compression fractures has a larger genetic 
component [75]. These results are interesting, because as discussed earlier, vertebral 
compression fractures are a good indicator of osteoporosis, and could possibly identify a 





1.5 Genetic correlation between traits 
 
1.5.1 How much does proxy variables like BMD tell us? 
Can genetic studies on bone parameters tell us anything about fracture risk? It is evident, that 
a fracture is the most important feature of osteoporosis in both adults and children. We also 
know that osteoporosis increases the risk of fractures, simply because fractures are 
encompassed in the (broader) definition of osteoporosis for both children and adults [1]. 
Deciphering the underlying mechanisms in osteoporosis should therefore also reveal 
underlying mechanisms for fractures. However, since BMD is the basis for the diagnosis of 
osteoporosis, the question is whether deciphering the underlying mechanisms for BMD can 
help to decipher the underlying mechanisms for fractures? A recent article using the 
FRISBEE cohort (Fracture Risk Brussels Epidemiological Enquiry), consisting of 3560 post-
menopausal women, investigated the risk of fractures in relation to BMD and other clinical 
risk factors. The authors could conclude that the best independent predictors of a future 
fracture were a diagnosis of osteoporosis, BMD (measured at several sites) and previous 
fractures [76]. Also, Kanis et al. performed a meta-analysis of 9 different population-based 
studies and the authors could clearly show that BMD, as a single predictor, was superior for 
fracture prediction compared to other clinical risk factors [77]. However, even if BMD is a 
better predictor for fractures than other risk factors or measurements, this does not mean that 
BMD fully explains why fractures occur. The above-mentioned study from Kanis et al. 
shows that their model for fracture prediction improves when BMD is combined with other 
clinically relevant risk factors. Professor Kanis is also the father of FRAX, the most widely 
used tool in clinical practice for fracture risk assessment [78]. The FRAX algorithm predicts 
fractures better than BMD alone, and it does this by using 11 different variables in addition to 
BMD. Although the FRAX algorithm has been criticized, it clearly shows that fracture 
models can be improved by adding additional information beyond BMD [79]. The fracture 
rate in the elderly population is especially high in the Scandinavian countries, particularly in 
Sweden. In fact, Sweden has the highest rate of osteoporotic fractures in the world. Eklund et 
al. performed a study in a large Swedish cohort, mainly consisting of at-risk individuals, to 
investigate this phenomenon [80]. The authors showed that despite the high fracture 
prevalence in the Swedish cohort, the Swedish participants did not have a lower BMD than 
at-risk individuals belonging to similar cohorts from other countries where the fracture rates 
are lower. The results highlight that BMD, although informative, cannot alone explain all 
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fractures. But taken together there is evidence that a proportion of the underlying mechanisms 
for BMD and fractures could be the same.  
 
1.5.2 Shared genetics between BMD and fractures 
Despite the acknowledged shortcomings, BMD is still a good indicator of bone health, and 
insights into the biology of BMD can provide useful information on bone metabolism and 
mechanisms leading to bone fragility and fractures. We know that BMD has a high 
heritability, and although the heritability seen in fractures is lower, fractures still have a 
substantial genetic component. As discussed above, there is reason to believe that some of the 
underlying mechanisms for BMD and fractures are shared. From a genetic perspective the 
interesting question is whether also the genetic mechanisms underlying BMD variability and 
fracture risk are shared, i.e. can the results from genetic studies on BMD be extrapolated to 
fractures. Benjamin Neale and his lab (http://www.nealelab.is) have done extensive work on 
calculating heritability of different traits using LD score regression from UK biobank data 
[69, 70]. However, LD score regression can also be used to assess genetic correlation (rg) 
between traits, a measurement of how similar the underlying genetics of two different traits 
are [81]. In short, genetic correlation can be estimated by quantifying the similarity of the 
association signals from two different GWASes that focus on separate traits. Identifying 
genetic correlations between traits can thus be used to mechanistically group traits together 
and help to shed light on relationships between traits that otherwise could be hard to foresee. 
Genetic correlations can also help to understand if results from genetic studies on proxy 
measurements such as BMD can be used to gain information on traits like fractures. The 
UKBB browser (https://ukbb-rg.hail.is) provides publicly accessible results from genetic 
correlations between hundreds of different traits within the UK biobank. Data from the 
UKBB browser is presented in Fig. 2 to visualize how BMD and fractures are genetically 
correlated, both to each other as well as to other traits. Specifically, the BMD trait in Fig. 2 is 
‘ultrasound derived heel BMD’ and the fracture trait is defined as ‘fractures within the past 5 
years’. Because of the large number of traits being compared (≈700), the results have been 
adjusted for multiple testing and only genetic correlations with a false discovery rate (FDR) 
≤0.05 are shown. Of all traits tested, ultrasound derived heel BMD correlates best with the 
diagnosis of osteoporosis (DXA-derived diagnosis), which was expected. However, more 
interesting is that it also genetically correlates quite well with fractures, indicating that 
ultrasound-derived heel BMD can be a good proxy measurement for genetic bone studies. 




Fig.2. Genetic correlation. The genetic correlation, representing shared underlying genetics, between fractures 
and BMD is large, suggesting that genetic results from studies on BMD can be extrapolated to fracture genetics. 
However, it is clear that the genetic component underlying fractures is more complex than for BMD. A) 
Significant genetic correlations between fractures and 297 different traits. Fractures are here defined as ‘fractures 
within the past 5 years’. B) Significant genetic correlations between BMD and 78 different traits. BMD is here 
defined as ‘quantitative ultrasound-derived BMD’. Data have been downloaded from the UKBB browser 
(https://ukbb-rg.hail.is). 
 
Although fractures are genetically highly correlated to different types of heel BMD 
measurements, fractures also show shared genetics with ‘mental illness’, ‘risk taking’, 
‘smoking’ and ‘risk of falls’. It is important to understand that genetic correlation results do 
not necessarily allow for a straight forward interpretation. As an example, the genetic 
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correlation observed between ‘risk of falls’ and ‘fractures’ could be the result of a genetic 
variant giving rise to a neurological disease that impairs balance, which then in turn leads to 
both falls and fractures. Thus, shared genetics does not always mean that a close relationship 
exists between the traits A and B. Instead a genetic variant increasing the risk for trait C, 
where trait A and trait B are consequences of trait C, could actually be the best explanation 
for the results seen. 
  
The results from the genetic correlation analysis provide support for heel BMD 
measurements as useful and meaningful parameters in genetic studies focused on 
osteoporosis and/or fractures. However, it cannot be assumed that all genetic findings from 
heel BMD measurements will be biologically relevant for osteoporosis. Even less information 
can be expected to be gained for fractures, also because the fracture is a less heritable trait. 
Due to the reasons above, there is a limit for how much information a proxy measurement 
can yield.  
 
1.5.3 Other proxy measurements 
So far, I have been somewhat critical to the use of proxy measurements. However, this is 
merely to point out that there are limitations in using such an approach, but if these 
limitations are recognized, using proxy measurements is an easy, good and valid approach. 
Using a more targeted proxy measurement to investigative bone metabolism, for example 
serum calcium level, vitamin D status or PTH dynamics, can also reveal new insights. The 
use of such narrow proxy measurements could be compared to using a monogenic approach 
in the sense that perhaps only one, or at best a few, underlying mechanisms can be anticipated 
to be revealed by the study. In analogy with the monogenic approach, such studies would 
help to build the puzzle one piece at a time. If 25-hydroxyvitamin D (25(OH)D) can be 
considered a narrow proxy measurement, BMD would be considered a broad measurement, 
but as long as there is a good reason to believe that the chosen study measurement is 
biologically related to the trait of interest (bone metabolism), new insights can be gained. In 
this thesis we have directed special attention, in addition to BMD and fractures, also to 
25(OH)D, a substance that has been implicated in various health outcomes and continues to 
be extensively studied [82]. The biological link between vitamin D and bone is clear, but 







2 AIM OF THESIS 
As the title of the thesis “Genetic causes and underlying disease mechanisms in early-onset 
osteoporosis” implies, the overall aim of our studies was to better understand the biology of 
bone metabolism by using a genetic approach.  
 
The specific aims were: 
1) To identify novel genetic causes of early-onset osteoporosis in affected individuals, 
families or cohorts.  
2)  To link the genetic findings to underlying biological mechanisms in order to expand 






3 PATIENT COHORTS 
 
3.1. Rare Phenotype Cohort 
As part of an ongoing research program, we have recruited single individuals and families 
with bone fragility disorders of unknown etiology, but where an underlying genetic cause is 
suspected. The recruited individuals and families all had bone-related disorders and the great 
majority of the affected individuals fulfilled the ISCD criteria for primary osteoporosis in 
children. In patients not fulfilling the strict ISCD criteria, individual assessment of 
radiographs and fracture history still strongly suggested increased bone fragility and primary 
osteoporosis. The individuals were extensively phenotyped and a careful clinical and 
biochemical investigation excluded secondary osteoporosis. The most common monogenic 
causes of osteoporosis had been genetically excluded in the majority of the patients. Bone 
biopsies were performed when possible, either as part of the clinical investigation or because 
of research interest. Individuals from this research effort are included in Paper I-III. In Paper 
III a phenotypically similar cohort from Canada was also included.  
 
Aim of genetic studies in the Rare Phenotype Cohort 
The main aim of conducting genetic studies in this cohort / type of cohort, is to find novel 
monogenic causes of disease, including both the discovery of novel variants in known disease 
genes and discovery of novel disease genes. Naturally, implicating novel genes in a disease 
often reveals more interesting biological information than the discovery of novel variants in 
known genes. However, in monogenic osteoporosis, as in many other genetic disorders, 
exploring the allelic heterogeneity can yield relevant information to explain the often-seen 
variable expressivity. In OI glycine substitutions in COL1A1 often are lethal, while nonsense 
variants in the same gene cause a much milder phenotype. Furthermore, pathogenic variants 
at certain specific locations in the genes COL1A1 and COL1A2 lead to Ehlers-Danlos 
syndrome rather than OI [86]. Genetic studies in this kind of rare phenotype cohorts can also 
be carried out to validate new scientific findings using a candidate gene approach, to screen 
for the presence of pathogenetic variants in recently discovered genes. The first approach was 




3.2. Fracture-Prone Children Cohort 
This cohort consisted of 64 healthy children, without prior diagnosis or suspicion of primary 
osteoporosis, but with unusual propensity to fracture. This cohort was collected as part of a 
prospective epidemiological study at the Children's Hospital, Helsinki, Finland [87]. All 
children aged 4-15 years (n=1412) who during a 12-month period had been treated for an 
acute fracture were also questioned about previous fracture history. All children meeting the 
criteria for a clinically significant fracture history (n=71) were invited to take part in this 
research study. The inclusion criteria were: (1) age 4-15 years; (2) ≥ 2 low-energy long bone 
fractures before age 10 years; or (3) ≥ 3 low-energy long bone fractures before age 16 years; 
or (4) ≥ 1 low-energy vertebral fracture (loss of ≥ 20% vertebral height). Children with 
suspected secondary osteoporosis were excluded, as were children with a previous diagnosis 
of OI or suspicion of OI. The current ISCD criteria for a pathological fracture history in 
children are largely based on this study. The Fracture-Prone Children Cohort was included in 
Paper I and Paper III.  
 
Aim of genetic studies in the Fracture-Prone Children Cohort 
The distribution of childhood fracture in Finland is best represented by a Poisson distribution 
with a low mean [88]. The children in the Fracture Prone Children Cohort represent the tail of 
this distribution. However, a simple simulation exercise (unpublished) suggests that a slightly 
greater number of children meet the inclusion fracture criteria than what would be expected 
from Finnish age-adjusted fracture frequencies [88]. Since this cohort includes otherwise 
healthy children with a less severe bone phenotype, the underlying causes for their fractures 
are probably more heterogeneous. It is reasonable to believe that environmental or random 
factors will explain some (or perhaps a large proportion) of cases, while the sum of 
polygenetic contributions could explain another proportion. We also hypothesized that a 
minor proportion could be explained by single monogenic variants, which might have a less 
damaging effect than those present in severe forms of osteoporosis, or monoallelic variants 
with a damaging effect in genes usually associated with a recessive disease. This cohort was 
studied in Papers I and III: Paper I focuses on a monogenic approach, while Paper III aims to 





3.3. The VIDI Cohort 
Vitamin D and its effect on health outcomes in general, and on skeletal outcomes in 
particular, have over the years drawn a large research interest. In vitro and in vivo studies 
have suggested vitamin D to be an important substance, in particular for bone, but not all 
randomized clinical trials have been able to replicate vitamin D’s proposed positive effects 
[89]. However, more research is needed, especially to determine how geographical location 
and age affect response to vitamin D and what is the optimal serum 25(OH)D concentration 
for bone health. 
The VIDI Cohort was recruited to evaluate the effects of different supplemental vitamin D 
dosages in Finnish infants [90, 91]. In short, the VIDI study was a randomized clinical trial 
that included 975 new-born healthy infants, born to healthy mothers at the Kätilöopisto 
Helsinki Maternity Hospital in Finland. All included children were born at term and had a 
birth weight within the normal range [92]. The original study investigated whether a daily 
dose of 30 µg of vitamin D3 (intervention dose) compared to a daily dose of 10 µg (standard 
dose), initiated at the age of 2 weeks, had an impact on bone strength, measured by peripheral 
quantitative computed tomography (pQCT), and on infectious outcomes at age 24 months. 
However, one objective was also to study genetic variation in relation to serum 25(OH)D 
concentrations, vitamin D supplemental response, and skeletal and infectious outcomes. The 
VIDI Cohort’s polygenic structure is studied in Paper III and Paper IV. 
 
Aim of genetic studies in the VIDI Cohort 
This cohort consist of healthy children, all with healthy mothers of Northern European 
decent, and who were all recruited at the same medical center. Also, by study design, all 
children have the exact same age at each point of measurement. Based on how this cohort 
was collected and how the follow-up visits were performed, it can be argued that it has a very 
homogeneous composition for a population-based cohort, both when it comes to background 
genetics and obtained study measurements. Both 25(OH)D concentrations and pQCT 
parameters, which were the focus of the study, are complex traits with high heritability 
estimates [49, 93]. To study the underlying genetics of these traits, an approach that can 








4.1 Genetic methods 
Sanger sequencing (Paper I). Genomic DNA was extracted from peripheral blood. Sanger 
sequencing was sequentially performed using BigDye® technology on a 3730 ABI 
sequencer. Primer3Plus was used for PCR primer construction.  
 
Massive parallel sequencing (Paper I and II). Genomic DNA was extracted from 
peripheral blood. Whole exome sequencing was performed both at Science for Life 
Laboratory, Stockholm, Sweden and Oxford Gene Technologies, Oxfordshire, UK using 
Illumina technology. Agilent SureSelect enrichment kits were used for whole-exome capture. 
The Speedseq framework [94] was used for alignment and variant calling and variant 
exploration was primarily performed using GEMINI (0.18.3) [95] and BEDTools [96]. All 
computations were performed on resources provided by SNIC through Uppsala 
Multidisciplinary Center for Advanced Computational Science (UPPMAX)[97]. 
 
Array comparative genomic hybridization (array-CGH) (Paper II). A custom designed 
2x400K array from Agilent Technologies that was enriched with probes in over 300 genes 
known to underlie skeletal disorders. The Agilent Genomic Workbench 7.0 was used to 
analyze the results.  
 
Genome wide genotyping (Papers III and IV). Individuals from the Rare Phenotype 
Cohort, the Fracture-Prone Cohort and the VIDI Cohort were genotyped using the Illumina 
Infinium Global Screening Array v1.0 at the Human Genomics Facility (HuGe-F) at 
Erasmus MC, Netherlands. In total 686,085 different genomic positions were genotyped. 
Reference populations from the Haplotype reference consortium and 1000 Genomes phase 
3 were used for haplotype estimation and imputation [98, 99]. Association tests were 
conducted using Plink (v 1.9) [100], FlashPCA was used to conduct principal component 




4.2 Measurement of skeletal characteristics 
Bone densitometry (Papers I and II). Dual-energy X-ray absorptiometry (DXA) 
measurements were performed using GE Lunar Prodigy (Madison, WI, USA) and Hologic 
QDR Discovery device (Hologic Inc., Waltham, MA, USA). Z-scores were calculated using 
either published or equipment-specific references accounting for age- and sex. 
 
Peripheral quantitative computed tomography (pQCT) (Paper IV). pQCT 
measurements, using Stratec XCT2000LResearch+; Stratec Medizintechnik GmbH, were 
obtained at the 20% distal site of the left tibia [90]. Three pQCT parameters (bone mineral 
density, bone mineral content and cross-sectional area) for both total and cortical bone were 
used for analyses. 
 
4.3 Evaluation of bone tissue characteristics 
Bone histomorphometry (Papers I and II). Transiliac bone biopsies were obtained after a 
double course of oral tetracycline. In Paper I bone biopsies were analyzed using a 
semiautomatic image analyzer (Bioquant Osteo; Bioquant Image Analysis Corp., Nashville, 
TN, USA). In Paper II bone biopsies were analyzed using an Axiophot light microscope 
combined with a confocal laser scanning microscope (CLSM) (Leica TCS_SP5, Leica 
Microsystems, Wetzlar, Germany). Double tetracycline labels were used to assess bone 
turnover and bone tissue dynamics. 
 
Quantitative Backscattered Electron Imaging (qBEI) (Paper II): 
The qBEI analysis of the transiliac bone biopsy in Paper II was performed using a Zeiss 
Supra 40 scanning electron microscope that had a spatial resolution of 1.8 µm/pixel. Bone 






Raman microspectroscopy (Paper II):. For the Raman microspectroscopy a Senterra 
instrument was used (Bruker Optics GmbH Ettlingen, Germany).  
 
For a detail description of the methods concerning bone tissue characteristics, please see 
Supplemental appendix in Paper II. 
 
4.4 Biochemical measurements (Paper IV) 
Vitamin D measurements. The 25(OH)D in serum was measured at 12 and 24 months. At 
birth 25(OH)D was taken from umbilical cord blood. The 25(OH)D measurement at 24 
months was used for the association analysis because it was assessed as the measurement best 
reflecting the children’s inherent 25(OH)D concentrations. 
 
Biochemical analyses in Papers I-III were performed during the clinical assessment to 
exclude secondary osteoporosis.  
 
4.5 Statistical analyses  
Statistics (Paper I-IV). The software R (version 3.3.1 – 3.3.5) was used for statistics, high 






5 RESULTS AND DISCUSSION 
 
5.1 Paper I 
Analyzed cohorts: 1) Rare Phenotype Cohort and 2) Fracture-Prone Children Cohort. 
 
PLS3 sequencing in childhood-onset primary osteoporosis identifies two novel disease-
causing variants. Paper I had a simple and straight forward approach. At the time of the 
study, pathogenetic variants in PLS3 had just recently been shown to be the cause of an X-
linked form of early-onset primary osteoporosis [105, 106]. The aim of the study was to 
investigate whether we can identify novel PLS3 variants in the Rare Phenotype Cohort and/or 
in the Fracture-Prone Children Cohort. The results aimed to clarify weather PLS3 screening 
should be recommended in clinical practice for patients with primary osteoporosis or an OI-
like bone phenotype. Further, the study aimed to investigate weather variants in the X-
chromosomal gene PLS3 could explain milder bone phenotypes, such recurrent fractures in 
childhood, because it is well known that boys have a higher fracture rate than girls [107, 108]. 
For this purpose, all coding exons and flanking intronic regions were screened for pathogenic 
variants in PLS3 for 31 patients in the Rare Phenotype Cohort and 64 children in the 
Fracture-Prone Children Cohort. 
 
Novel PLS3 variants in children with primary osteoporosis. In the Rare Phenotype 
Cohort, the sequencing results revealed that two individuals harbored novel PLS3 variants 
that was deemed to be the cause of their bone phenotypes. The two individuals with 
damaging PLS3 variants both had severe vertebral compression fractures and very low BMD, 
even in relation to other children with primary osteoporosis [Fig. 3]. The Rare Phenotype 
Cohort comprised 31 patients who had been investigated at the Metabolic Bone Clinic, 
Children’s Hospital, Helsinki because of primary osteoporosis, but without an identified 
molecular cause. Most of the 31 patients fulfill the ISCD pediatric criteria for primary 
osteoporosis, but 6 individuals did not. However, we believe that this type of inclusion 
criteria, which are not only built on static parameters but also on careful individual clinical 
assessments, are more likely to identify individuals suited for genetic studies. The individuals 
in this cohort often had a family history that suggested an inherited disorder, even though the 
inheritance pattern seldom provided indisputable evidence for a monogenic cause. 
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Fig. 3. BMD measurements in the Rare Phenotype Cohort. DXA-derived BMD measurements for the 31 
individuals in the Rare Phenotype Cohort included in Paper I. The two individuals with novel disease-causing 
PLS3 variants (circled) have an exceptionally low BMD both at the lumbar spine and at the femoral neck. 
[Vertebral compression fractures (VCFs), please also note that not all BMD measurements in this cohort are 
bisphosphonate treatment naïve.] 
 
Patient I was diagnosed with multiple vertebral compression fractures at the age of 10 years 
and had before that broken both his femurs at two separate occasions. He was discovered to 
have a novel nonsense variant (p.Arg256*) in PLS3, classified as pathogenic (class V) 
according to the ACMG criteria [109]. The variant was inherited from his healthy mother. 
Patient II, at the time 10 years of age, also had a fracture history that included multiple 
peripheral and vertebral compression fractures. She also had an exceptionally low BMD, with 
a lumbar spine DXA-derived Z-score of -6.6. Patient II was discovered to have a 
heterozygous de novo missense variant in PLS3, which was consistent with her parents’ lack 
of fracture history. The variant (p.Asn446Ser) could be classified as likely pathogenic (class 
IV) according to the ACMG criteria, which is regarded as clinically actionable. Because the 
significance of a heterozygous variant in the X-chromosomal PLS3 is more difficult to 
interpret in girls, we also performed an array-CGH in the girl and WES of her nuclear family 
without being able to find another plausible genetic explanation. However, it is known that 
the female disease spectrum in PLS3 osteoporosis is wide, and females also within the same 
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family can have mild to severe disease [106]. The results in Paper I indicate that screening for 
PLS3 sequence variants is indicated in boys and girls with primary osteoporosis of unknown 
cause, especially if spinal fractures are a dominant feature. 
 
PLS3 variants are not common in children with mild bone phenotypes. The majority of 
children in the Fracture-Prone Children Cohort were, as expected, boys (43 boys vs 21 girls). 
Although there are a number of reasons why boys might be more prone to fractures than girls, 
genetic explanations related to the X-chromosome are possible. However, in this cohort we 
identified no rare or damaging variants in PLS3, suggesting that PLS3 is not a common cause 
for milder bone phenotypes with recurrent fractures but normal BMD and that PLS3 variants 
cannot explain the observed gender differences in fracture rates. From inclusion design and 
from what we know about fracture rates in children [88], random accidents and 
environmental factors will probably explain a large proportion of fractures, also in this 
cohort. Based on the way fractures are distributed, a genetic cause in this cohort would be 
more likely to be polygenic in nature, and not monogenic. In that perspective our negative 
results were expected since only a minor proportion of the Facture-Prone Children Cohort 
could be suspected to have an underlying monogenic cause for their fractures. Still, it can be 
argued that this type of candidate-gene approach is valid, also in a cohort such as this one. 
The genetic causes for increased fracture tendency in childhood, and for male predominance 
in those with multiple fractures, remain inadequately understood and in that regard our study 
provided novel information, despite the negative findings. An oligogenic scenario is also 
possible, in which some of the fracture-prone individuals would have functional and 
relatively rare variants in PLS3 that would confer a moderate fracture risk. In such a scenario, 
positive results would be possible to obtain also in a cohort such as this one. Previous studies 
have also indicated that common variants in PLS3 could confer a slightly increased risk of 





5.2 Paper II 
Analyzed cohorts: 1) Rare Phenotype Cohort 
 
PLS3 deletions lead to severe spinal osteoporosis and disturbed bone matrix mineralization. In 
this study we identified two large PLS3 deletions in patients from two different families. At 
the time of the study, no gene deletions in PLS3 had been reported. Family I consisted of two 
siblings, both boys, with severe and almost identical bone phenotype that differed from 
classical OI. The parents were healthy. Secondary causes had been excluded and because of 
the specific bone phenotype in the two brothers, a monogenic condition was strongly 
suspected. Whole exome sequencing was performed for the entire nuclear family. No 
sequence variants were found in our in-house OI gene panel, and no other plausible causative 
variants consistent with the inheritance pattern could be found in the exome-wide analysis. 
However, a read-depth analysis for all OI-genes included in the gene panel revealed a large 
deletion in PLS3 spanning exons 4-16 in hemizygous form in both boys. The deletion was 
inherited from their heterozygous, but healthy, mother [Fig. 4]. 
 
 
Fig.4. A large deletion in PLS3. Read depth plots for all coding exons of PLS3 in Family I. A) The two brothers 
(orange and green) have no reads mapping to exon 4-16 in PLS3, indicating a hemizygous deletion. B) 
Comparing the read depth ratio between the father and the mother (pink and purple) show that the they have an 
equal amount of reads mapping to exon 4-16 in PLS3, indicating a heterozygous deletion in the mother for the 




Normally whole exome sequencing (WES) is not a good method for analyzing structural 
variants because of very uneven read-depths and an improbability of capturing SV break 
points. Instead, whole genome sequencing (WGS) is preferred [110]. Fig. 5 visualizes the 
variability in read depth between the two methods (unpublished data). However, WES still 
has the possibility to identify larger deletions in preselected genes, but for duplications this 
possibility is limited. 
  
Fig. 5. Read depth variability between WES and WGS for an in-house OI gene panel. As can be seen, 
WGS provides more stable and less variable data and therefore perform much better when analyzing structural 
variants (SVs). However, homozygous or hemizygous deletions can be detected also by WES, at least for pre-
specified genes.   
In Family II an array-CGH identified a complete gene deletion in PLS3 in a 12-year-old boy 
with a very low BMD and vertebral compression fractures. This study thus identified two 
novel PLS3 deletions. Shortly after our publication, another group also published a case 
report on a young boy with a notably low BMD and multiple vertebral compression fractures, 
who also harbored a large deletion in PLS3 [111]. In all described individuals with PLS3 
deletions the affected individuals (boys) have had a severe skeletal phenotype, including a 
very low BMD, but particularly, severe spinal osteoporosis with multiple vertebral 
compression fractures.  
 
PLS3 gene deletions lead to disturbed bone matrix mineralization. Large, or complete, 
deletions of a gene can with certainty be regarded as functional null variants and can 
therefore be used to study how different tissues react to the absence of a protein. As 
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previously discussed, careful and correct phenotyping to select the appropriate patients for 
genetic studies is very important in order to be successfully able to discover underlying 
genetic causes. However, when an underlying genetic cause has been identified, extensive 
tissue phenotyping needs to be performed to uncover the mechanisms affected by that same 
genetic aberration. In this study, we were able to confirm previous reports that spinal 
osteoporosis, and in particular, vertebral compression fractures should be considered a 
hallmark of PLS3 osteoporosis. A bone biopsy was also taken from the index case in Family I 
and extensively analyzed. The results from the bone histomorphometry showed a clear 
increase in mineralizing lag time as well as an increase in osteoid volume, surface and 
thickness. The quantitative backscattered electron imaging (qBEI) showed a strong 
hypomineralization of the bone matrix and a broadened bone mineral density distribution 
peak, suggesting that the mineralization was spatially heterogenous. The hypomineralization 
could also be detected by Raman microspectroscopy which showed a markedly low 
mineral/matrix ratio and a decrease in glycosaminoglycans, proteoglycans and pyridinoline, 
suggesting that the bone composition was also altered. Because of double tetracycline labels 
the dynamics in bone deposition could be assessed by analyzing altogether four different 
tissue ages. Collectively the results indicated that the PLS3 deletion led to a disturbed bone 
matrix mineralization, which also was supported also by the results by Wesseling-Perry et al. 
[112].  
 
During bone matrix mineralization hydroxyapatite crystals are formed within the lumen of 
matrix vesicles released from chondrocytes into the extra cellular matrix (ECM) [113]. 
Because PLS3 has been shown to be expressed in these released matrix vesicles from 
mineralizing cells, and because PLS3 is known to be involved in the regulation of the actin 
cytoskeleton, it is possible that PLS3 plays an important role for bone matrix mineralization 
[114-116]. Although our study could not pinpoint the exact role of PLS3 in bone matrix 
mineralization, our results give strong support for the suggestion that PLS3 is directly 
involved in the process. At the time of the study, and even presently, very little was known 
about PLS3’s function in bone. Our results provided evidence that PLS3 has a major role in 
primary mineralization of the bone matrix, which has also recently received support from 
mouse studies [117]. The results highlight the strength of careful and precise phenotyping, 
because the study was able to produce meaningful novel results while using standard methods 
on very few individuals.  
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5.3 Paper III 
Analyzed cohorts: 1) Rare Phenotype Cohort; 2) Fracture-Prone Children Cohort and 3) The 
VIDI Cohort 
 
Increased burden of common risk alleles in children with a significant fracture history. 
In Paper III the aim was to assess the polygenetic contribution to rare and severe bone 
phenotypes in children. As discussed throughout this thesis, we often suspect that children 
presenting with primary osteoporosis have a monogenic cause for their disease. In children 
whose standard gene panel has been negative, it is common to reason that an expanded 
genetic investigation using WES or WGS could identify novel genetic causes for primary 
osteoporosis. In our Rare Phenotype Cohort, although monogenic causes are primarily 
suspected, the observed inheritance pattern seldom excluded other causes. For this purpose, 
we used a polygenic risk score derived from genetic association data from the UK biobank on 
heel quantitative ultrasound speed of sound. The polygenic risk score, called gSOS, has been 
validated and shown to predict fractures in a large cohort of adult individuals, also from the 
UK biobank [118].  
 
A polygenic risk score derived from quantitative ultrasound of the heel. Findings from 
GWASes can be used to identify genomic loci important for a trait and help to decipher 
underlying mechanisms for that trait. However, a single SNP associated with a trait only 
explains a very small fraction of the genetic variance of the associated trait, but the sum of all 
associated SNPs might explain a larger fraction. A polygenic risk score is a way to quantify 
all available genetic information, to measure the sum of the genetic effects. As discussed in 
the introduction, BMD can be estimated from quantitative ultrasound of the heel (eBMD), 
which is a good proxy measurement for DXA-derived BMD and has a fair correlation with 
fractures [57, 119]. The results from genetic correlation analyses [Fig. 2] also suggest shared 
inheritance between ultrasound derived heel BMD, osteoporosis and fractures. To be precise, 
eBMD is derived from quantitative ultrasound index (QUI) which is a combination of the two 
quantitative ultrasound variables 1) speed of sound (SOS) and 2) broadband ultrasound 
attenuation (BUA). In this study the polygenic risk score was developed only from heel 
quantitative ultrasound SOS, but the correlation between SOS and QUI is very high (r>0.9) 
and SOS is also independently associated with fractures [118-121]. The polygenic risk score 
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was developed, using machine learning algorithms, from an underlying GWAS that included 
341,449 individuals and validated for fracture prediction in a set of 80,027 individuals. The 
final polygenic risk score (gSOS) included 21,717 genomic markers and could predict 
fractures just as well as measured SOS and DXA-derived hip BMD [118], suggesting that the 
score has the capability to assess bone health. In our study, the polygenic risk score was not 
used to predict fractures. Instead we hypothesized that children with a polygenic cause of 
their bone phenotypes would have a lower gSOS score compared with a normal population. 
However, for children with bone phenotypes due to monogenic variants, the gSOS score 
should not be impacted. The aim was therefore to use gSOS scores to assess etiology at the 
cohort level.  
 
Evidence for polygenic contribution in children with primary osteoporosis. This study 
comprised four different types of cohorts: The Rare Phenotype Cohort from Finland, A Rare 
Phenotype Cohort from Canada, The Fracture-Prone Children Cohort and the VIDI Cohort. 
The two Rare Phenotype Cohorts included 18 individuals from Finland and 60 individuals 
from Canada, all with a suspected monogenic bone disorder with childhood-onset, for which 
a molecular cause could not be identified. The majority of the children in these two cohorts 
would qualify for the diagnosis primary osteoporosis. The results showed that the polygenic 
risk score was significantly lower in these two rare phenotype cohorts than the gSOS score in 
the normal reference population from the UK biobank. Because the gSOS score was derived 
from an adult population, as well as the UK biobank reference used for comparison, we also 
included another reference cohort consisting of 898 healthy Finnish children (the VIDI 
Cohort), but the results remained the same [Table 2]. The VIDI Cohort had a very similar 
gSOS score as the UK biobank reference, suggesting that the gSOS score is valid also for 
pediatric cohorts and that the study results can be trusted. The results provide evidence that a 
proportion of children with primary osteoporosis and a clinical suspicion of a monogenic 
cause actually have a polygenic cause of their disease. The gSOS score was developed from 
heel quantitative ultrasound speed of sound, which is a legitimate proxy measurement for 
bone health, but it cannot serve as a replacement of a more careful phenotype assessment. It 
is therefore reasonable to believe that the gSOS score only captures a part of the polygenic 
contribution to osteoporosis in these children, meaning that the polygenic contribution in 
childhood primary osteoporosis is likely to be larger than what we can show in this study. 
However, because of the small sample sizes in our study, the results would need to be 
replicated before far-reaching conclusions can be drawn.  
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gSOS score (SD) 
 
p-value 
(vs UK Biobank reference) 
Reference datasets 
  
UK Biobank (n = 80,027) 0.00 (1.00)  NA 
VIDI Cohort (n = 898) 0.01 (1.00) 0.69 
   
More severe bone phenotypes 
  
Rare Phenotype Cohort (Canada, n = 60) −0.82 (0.90) 3.7 × 10−9 
Rare Phenotype Cohort (Finland, n = 18) −0.54 (1.01) 0.04 
Rare Phenotype Cohorts combined (n = 78) −0.76 (1.06) 5.3 × 10−10 
   
Milder bone phenotypes 
  
Fracture-Prone Cohort (Finland, n = 53) −0.04 (1.06) 0.77 
   
Combined analysis 
  
All study Cohorts combined (n = 131) −0.47 (1.00) 1.1 × 10−5 
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No evidence for a polygenetic etiology in milder phenotypes. The last cohort evaluated 
with the gSOS score was the Fracture-Prone Children Cohort, in which the children had a 
milder bone phenotype. We recognize that this cohort is heterogeneous, but due to reasons 
previously stated, we hypothesized that polygenic causes could explain a sizable proportion 
of the fracture susceptibility in this cohort. However, the gSOS score for the entire cohort 
was not significantly different from the UK biobank reference. Analyzing the cohort as a 
whole, the results suggest that polygenic factors do not explain this milder bone phenotype 
in children. Instead, it might be likely that the presumed fracture susceptibility could be 
explained largely by exogenous or environmental factors. Interestingly though, when 
stratifying the Fracture-Prone Children Cohort based on whether or not they meet the 
criteria for primary osteoporosis, interpretation of the results changes (unpublished sub-
analysis) [Fig. 6]. Using the healthy VIDI Cohort as the reference, which might be more 
appropriate when separately assessing the Finnish cohorts, the Rare Phenotype Cohort 
(n=18) had a significantly lower gSOS score than the VIDI Cohort (t-test, p=0.026). For the 
Fracture-Prone Children Cohort as a whole, no difference in gSOS score compared to the 
VIDI Cohort was seen (t-test, p=0.83). However, when dividing the Fracture-Prone 
Children Cohort into two subgroups: 1) children who fulfill the ISCD criteria for primary 
osteoporosis (n=15); 2) children who do not fulfill the ISCD criteria (N=40), the results 
change. The 15 children fulfilling the diagnosis of primary osteoporosis had a significantly 
lower gSOS score than the VIDI cohort (t-test, p=0.048). Looking at the density plot [Fig 
7B] it is also clear that the gSOS score is completely normally distributed in the VIDI 
Cohort as well as in the sub-group of the Fracture-Prone Children Cohort that did not fulfill 
the criteria for osteoporosis. For the children belonging to the Rare Phenotype Cohort and 
the children from the Fracture-Prone Children Cohort who did fulfill the criteria for 
osteoporosis, the density plots display two peaks. This suggest different underlying 
etiology, where a proportion of these children do have a polygenic cause for their 
osteoporosis, while the proportion with a normal gSOS score have a non-polygenic cause 
(note that the cause could still be monogenic). In summary, in children with fractures, 
support for a polygenic cause was only found for children with a more severe bone 
phenotype, but not for children with non-vertebral fractures and a normal BMD. Further, 
even though gSOS score cannot discriminate children with a polygenic bone disorder from 
those with a monogenic bone disorder on the individual level, the results strongly suggest 






Fig. 6. Density plot of the gSOS score distribution in the three Finnish cohorts. A) The Rare Phenotype Cohort 
had a significantly lower gSOS score compared to the healthy VIDI Cohort, while the Fracture-Prone Children 
Cohort had a similar gSOS score compared to the VIDI Cohort. B) Dividing the Fracture-Prone Children Cohort 
into two groups depending of whether they fulfill the criteria for osteoporosis (OP) changes the results. The 
subgroup of Fracture-Prone Children Cohort with osteoporosis have a significantly lower gSOS score than the 
VIDI Cohort. The double peaks in the density plot for the Rare Phenotype Cohort and for the subgroup of the 
Fracture-Prone Children Cohort with osteoporosis suggests that theses cohorts consist of two different 
populations, one that has a polygenic cause of disease and one that has a non-polygenic cause of disease.  
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5.4 Paper IV  
Analyzed Cohorts: 1) The VIDI Cohort 
 
Genetic variation in GC and CYP2R1 affects 25-hydroxyvitamin D concentration and 
skeletal parameters: A genome-wide association study in 24-month-old Finnish 
children. In Paper IV we performed a GWAS focused on 25(OH)D concentrations in 24-
month-old children. We were able to provide strong support that the genes GC (Vitamin D 
binding protein) and CYP2R1 (Vitamin D 25-hydroxylase) affect 25(OH)D concentration in 
24-month-old children, and that the gene GC might be important for vitamin D 
supplementation response. Furthermore, we could show that children with genetic 
constellations associating with lower vitamin D had lower BMD.  
 
Vitamin D is a prohormone important for both calcium and phosphate homeostasis and it 
has caught the interest of many research groups [122]. That vitamin D deficiency can cause 
rickets in children and osteomalacia in adults has been known for a long time. Both rickets 
and osteomalacia are disorders characterized by poor bone matrix mineralization. These 
disorders can also be regarded as evidence for the importance of vitamin D sufficiency for 
bone health [14, 15]. Positive effects of high concentrations of vitamin D have also been 
associated with several different health outcomes, including all-cause mortality, but the 
prohormone’s causal effect has been hard to prove [83-85]. However, because of the 
geographic location of the Nordic countries, having winters with long periods of little 
sunlight, low vitamin D concentrations have been a concern [123]. In Finland, vitamin D 
concentration has also been shown to be associated to BMD in adolescents [16]. The aim of 
Paper IV was to investigate genetic variation associated with serum 25(OH)D levels in 24-
month-old children. Because of the study design, also genetic variants associated with 
vitamin D supplementation response could be assessed. The study also set out to investigate 
vitamin D concentrations in relation to skeletal outcomes in these 24 month-old-children. 
Apart from severe vitamin D deficiency, it has been difficult to confidently prove positive 
skeletal effects of vitamin D. However, we hypothesized that because of Helsinki’s 
northern location and reduced cutaneous UV exposure, a genetic constellation that helps to 
ensure vitamin D sufficiency might be proportionally more important and genetic liabilities 
might thus be more easily revealed. Also, the extraordinary rapid skeletal growth rate 
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occurring in children from birth to 24 months could render the skeleton more vulnerable to 
small effects that might go undetected in adults.  
 
Small cohorts are usually not suitable for GWASes. Our GWAS on 25(OH)D, which is 
the metabolite used to determine vitamin D status, could be considered underpowered and 
very small for this type of approach. In comparison, a GWAS that was very recently 
published looked at genetic variation associated with 25(OH)D in more than 400,000 adult 
individuals [124]. However, we argue that the genetic homogeneity of the study cohort partly 
compensates for the small sample size. Furthermore, no GWAS on vitamin D has previously 
been performed in this age group. Moreover, because of the participants young age we 
believe that our study is less confounded by environmental and behavioral factors affecting 
an individual’s vitamin D status. As discussed above, because of the biologically dynamic 
situation during early childhood, the importance of genetic regions regulating vitamin D 
concentration might be easier to detect. Also, because the skeletal measurements were taken 
with high precision, using pQCT, when the children had exactly same age (24 months), we 
believe that our study has the possibility to reveal relationships and associations that are hard 
to detect in adults, despite our small samples size. Finland can also be regarded as a genetic 
isolate in Europe where founder effects have had a strong effect [125, 126] Therefore, it is 
possible that in an association study certain loci affecting vitamin D metabolism may be less 
difficult to identify in the Finnish population. 
 
GC and CYP2R1 are likely to affect 25(OH)D concentrations in children. The GWAS 
identified two strong association signals near the genes GC and CYP2R1 [Fig. 7]. To map 
these signals, we compared, and quantified, the similarities between the association results in 
our study to publicly available expression quantitative trait locus (eQTL) data from the GTEx 
project [Fig. 8] [127]. This allowed us to confidently map our two identified association 





Fig. 7. The GC and CYP2R1 loci. A view of the genomic regions surrounding the strongest associated SNPs in 
both loci. Based on simulation studies by Wu et al [128], a 200 kb target window was used as our presumed 
resolution. A) The GC gene is the only gene within this 200 kb target window on chromosome 4 and therefore 
our best candidate to underlie the signal. B) For the CYP2R1 locus, the genes PDE3B and CYP2R1 are both 






Fig 8. Mapping our association signals using GTEx eQTL data. Association results from our GWAS on 
25(OH)D in 24-month-old children compared to eQTL data from the GTEx project. All significant SNPs (FDR 
≤0.05), simultaneously present in both datasets, and within the 200 kb target window are displayed. Significant 
SNPs are color-coded dependent on association direction. As shown, all significant SNPs present in both 
datasets have a concordant direction of association, suggesting a shared underlying genetic cause for the signals 
in our study and the GTEx datasets. A) GC locus; tissue analyzed: Stomach. B) CYP2R1 locus; tissue analyzed: 
Thyroid. 
 
The GC and CYP2R1 genes have previously been shown to be associated to 25(HO)D in 
several GWASes [93, 129-133] and their functional importance for vitamin D metabolism is 
known [134, 135]. Fig. 9 illustrates how the association results from our study compare with 
all other GWASes on 25(OH)D that have been reported to the GWAS Catalog. Because we 
had umbilical cord 25(OH)D measurements, we were also able to assess genetic variation in 
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relation to vitamin D supplementation response, defined as the change in 25(OH)D from birth 
to 24 months. The study showed that the GC locus associated with the magnitude of 
25(OH)D change during intervention. Because the results strongly suggested that the 
association signal could be mapped to the gene GC, it is thus likely that the gene GC also 
underlies the association seen in how the children responded to vitamin D supplementation.  
 
Fig. 9. Comparison of significant associations in our study vs the GWAS catalog. The GWAS results from 
our study on 25(OH)D are presented above the line y=0, while all genome-wide significant SNPs reported to the 
GWAS Catalog are presented below the same line. As shown, the two genome-wide significant loci, near the 
genes GC and CYP2R1, identified in our study on 25(OH)D in 24-month-old children are located within the two 
strongest loci previously reported to associate with 25(OH)D. 
 
Support for causal positive effect of 25(OH)D on skeletal outcomes. We could observe 
from our data that the 25(OH)D concentration was significantly associated with several 
pQCT parameters. We also observed that the lead SNPs in the GC locus and the CYP2R1 
locus also associated with pQCT parameters in the same manner as 25(OH)D, but these 
associations did not reach statistical significance. In an effort to gain power, we identified the 
major haplotypes for the two genome-wide significant loci in the hope that we would capture 
more of the underlying genetic information. We could also show that the haplotypes 
associated more strongly to 25(OH)D than the lead SNPs alone, suggesting that the 
haplotypes indeed captured more information. When looking at combinatory effects we could 
show that the combination of the two loci’s risk haplotypes was additive, approximately 
doubling the effect seen on 25(OH)D. Using a single sample mendelian randomization 
approach we stratified the children based on their combination of 25(OH)D haplotypes and 
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associated these new haplotype groups to pQCT parameters. The results showed a strong 
association between a child’s genetic vitamin D constellation and pQCT parameters [Table 
3], suggesting that low 25(OH)D has a true negative impact on bone in 24-month-old 
children. Or, in other words, 25(OH)D is not only a marker for skeletal outcomes in 24-
month-old children, but a mediator of the actual effect.  
 
Table 3. Haplotypes associated with low 25(OH)D also associates to skeletal parameters when combined. 
 
pQCT parameter 
(Measured at the Tibia) 
Beta coefficient for 
haplotype status* 
Std. Error p-value 
    
Total bone    
Bone mineral density -31.8998 10.2872 0.00224** 
Bone mineral content -1.3693 0.9583 0.154736 
Cross-sectional area 9.9368 3.6646 0.00734** 
    
Cortical bone    
Cortical density -27.681 7.881 0.00056*** 
Cortical content -3.7949 1.1646 0.00134** 
Cortical area -3.1087 1.1568 0.007869** 
*The major haplotypes at both significant loci were identified and denoted [A] and [a] for the GC locus and [B] 
and [b] for the CYP2R1 locus. Because of high haplotype frequency we could assessed the combinatory effects 
by creating 3 new haplotype groups that included individuals with the haplotype status of either: [AABB] or 






6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
The field of bone genetics has rapidly grown in the 21st century. The widespread use of WES 
and WGS has revealed many new genes underlying monogenic bone disorders, which also 
has led to the discovery of new signaling pathways important for bone. GWASes have 
quickly evolved from merely being a method that could prove its own principle to a method 
providing clinically relevant information. In this thesis we have used different genetic 
methods to uncover underlying causes for primary bone disorders in children, with the hope 
to also learn more about the underlying biology of bone. Today’s DNA sequencing methods 
allow for a precise assessment for SNVs and short indels, but the addition of RNA 
sequencing data has proven useful for variant interpretation. Analysis of structural variants in 
the human genome is still a difficult task, but the technique has matured and public reference 
datasets are growing. I do therefore believe that there still are interesting genetic findings to 
be discovered in families and individuals with monogenic osteoporosis and that these 
additional methods will improve the success rate. Regarding GWASes I believe that the 
current methods will continue to reveal underlying genetics causes for bone disorders. The 
steady increase in sample size together with the combination of sequencing data to assess rare 
variants and more sophisticated statistical models will make the GWAS approach successful 
also in the future. I do believe that there is a sample size limit, and when that limit is 
exceeded, additional results will no longer be biologically relevant. However, we are not 
there yet. The precision in how the studied GWAS trait is measured can also be improved, 
and in my opinion, a refinement of the trait being studied could be a better way forward than 
sample size increase. 
 
To conclude, it is evident that much information is still to be extracted only using current 
methods. However, I also believe that the techniques in molecular biology are now mature 
enough for a more integrative approach. To understand the full picture, data must be 
combined. The combination of omics data, including genomics, proteomics, metabolomics, 
interactomics etc. will help us to understand how biology really works. This integrative 
approach is being adapted by researchers around the world, and I do believe that it is the way 
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